•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

A08747 Summary:

BILL NOA08747A
 
SAME ASSAME AS S08257-A
 
SPONSORYeger
 
COSPNSRBerger, Wieder, Kay, Septimo, Eachus
 
MLTSPNSR
 
 
Directs the department of health to establish an alternative payment methodology (APM) for federally qualified health centers to preserve and improve patient access to fertility care.
Go to top    

A08747 Actions:

BILL NOA08747A
 
06/02/2025referred to health
01/07/2026referred to health
01/29/2026amend and recommit to health
01/29/2026print number 8747a
Go to top

A08747 Memo:

NEW YORK STATE ASSEMBLY
MEMORANDUM IN SUPPORT OF LEGISLATION
submitted in accordance with Assembly Rule III, Sec 1(f)
 
BILL NUMBER: A8747A
 
SPONSOR: Yeger
  TITLE OF BILL: An act directing the department of health to establish an alternative payment methodology (APM) for federally qualified health centers to preserve and improve patient access to fertility care   PURPOSE: Requires the department of health to develop a supplemental Medicaid payment to federally qualified health centers for reimbursement for certain uncovered fertility drugs.   SUMMARY OF PROVISIONS: Section 1: Requires the Department of Health to establish a new Medicaid alternative payment methodology that results in a supplemental payment to Federally Qualified Health Centers in addition to other rates they receive. This alternative payment methodology would be an amount equal to the difference between (a) the aggregate amount the health center paid to acquire eligible injectable fertility drugs for Medicaid patients under Section 340B of the Federal Public Health Services Act between January 1-December 31, 2024, and (b) the aggregate amount the health center would have paid to acquire those drugs based on average wholesale acquisition cost for such drugs during the same period. Eligi- ble injectable fertility drugs are limited to Gonadotropin, GNRH Antag- onists, and GNRH Agonists. Section 2: Effective date.   JUSTIFICATION: In 2017, New York State became the first state to provide Medicaid coverage for some services related to fertility, including coverage for some forms of ovulation enhancing drugs. CMS approved a State Plan Amendment for this coverage, submitted by New York State, which included a 90-10% federal-state match. While approval at that time limited cover- age to office visits, ultrasounds, and other services, it also included limited coverage of prescription drugs that promote fertility. Unfortu- nately, the list of drugs only included four types of oral ovulation enhancing drugs. Since that time, more effective drugs have become available, including injectable ovulation enhancing drugs to treat fertility issues. Several federally qualified health centers currently provide fertility services to their patients, including those enrolled in Medicaid. While commercial insurers generally cover the full range of fertility treat- ments, including injectable ovulation enhancing drugs, Medicaid only Covers the less effective, oral drugs. This coverage imbalance results in Medicaid patients having to pay "out-of-pocket" for these more effec- tive drugs, while those with commercial insurance have these drugs covered by their insurance. To address this imbalance, some FQHCs assist their Medicaid patients in covering the out-of-pocket costs for these more effective injectable drugs but are significantly limited in the number of patients they can assist because of constrained financial resources. This bill will help address this coverage imbalance by providing FQHCs with a dedicated funding stream to offer the full range of fertility services to their patients enrolled in Medicaid.   PRIOR LEGISLATIVE HISTORY: 2025: Passed Senate   FISCAL IMPLICATION: None. Any supplemental payment is part of the already approved state plan amendment that the State allocated the funds in previous years as part of a 90-10% federal state match.   EFFECTIVE DATE: This act shall take effect immediately.
Go to top

A08747 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                         8747--A
 
                               2025-2026 Regular Sessions
 
                   IN ASSEMBLY
 
                                      June 2, 2025
                                       ___________
 
        Introduced  by  M.  of A. YEGER, BERGER, WIEDER, KAY, SEPTIMO, EACHUS --
          read once and referred to the Committee on Health  --  recommitted  to
          the  Committee on Health in accordance with Assembly Rule 3, sec. 2 --
          committee discharged, bill amended, ordered reprinted as  amended  and
          recommitted to said committee

        AN  ACT  directing  the department of health to establish an alternative
          payment methodology (APM) for federally qualified  health  centers  to
          preserve and improve patient access to fertility care
 
          The  People of the State of New York, represented in Senate and Assem-
        bly, do enact as follows:
 
     1    Section 1. Under the authority of state plan  amendment  #17-0058,  as
     2  amended by state plan amendment #23-0050, the department of health shall
     3  establish  an alternative payment methodology (APM) for federally quali-
     4  fied health centers to preserve and improve patient access to  fertility
     5  care.  Any  payments  made  under  the  APM  shall be in addition to any
     6  payments made under the prospective payment system (PPS)  or  any  other
     7  alternative  payment methodology for federally qualified health centers.
     8  The APM shall provide for payments to  be  made  by  the  department  of
     9  health  to  federally qualified health centers in an amount equal to the
    10  difference between (a) the  aggregate  amount  the  federally  qualified
    11  health  center  paid  to acquire eligible injectable fertility drugs for
    12  Medicaid patients under  section  340B  of  the  federal  public  health
    13  services  act  between January 1, 2024 and December 31, 2024 and (b) the
    14  aggregate amount the federally qualified health center would  have  paid
    15  to  acquire  those drugs based on average wholesale acquisition cost for
    16  such drugs during the same period. For purposes of this section,  eligi-
    17  ble  injectable  fertility  drugs shall be limited to gonadotropin, GNRH
    18  antagonists, and GNRH agonists.
    19    § 2. This act shall take effect immediately.

         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD09276-04-5
Go to top